SELLAS Life Sciences Group, Inc. Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs
SELLAS Life Sciences Group, Inc. (SLS) had Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs of $0 as of 2021-12-31, per its 10-K filed 2022-03-31.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Gross
us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts · last filed 2022-03-31
- 2021-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $0.00.
- 2020-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $1.20M.
- 2019-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $1.22M.
- 2018-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $1.78M.
| Period end | Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs |
|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-03-31 |
| 2020-12-31 | $1.20M 10-K · filed 2022-03-31 |
| 2019-12-31 | $1.22M 10-K · filed 2021-03-23 |
| 2018-12-31 | $1.78M 10-K · filed 2020-03-13 |
| 2017-12-31 | $3.44M 10-K · filed 2019-03-22 |
| 2016-12-31 | $5.66M 10-K · filed 2017-03-15 |
| 2015-12-31 | $5.42M 10-K · filed 2017-03-15 |
| 2014-12-31 | $5.05M 10-K/A · filed 2016-04-15 |
| 2013-12-31 | $5.05M 8-K · filed 2015-12-04 |
| 2012-12-31 | $5.05M 10-K · filed 2014-03-17 |
| 2011-12-31 | $5.05M 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |